Ascelia Pharma AB

Equities

ACE

SE0010573113

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:50 2024-04-26 am EDT			5-day change	1st Jan Change
11.16 ^SEK	+5.28%		-15.33%	+231.16%

Apr. 10	Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024	CI
Feb. 09	Ascelia Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Ascelia Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023

May 11, 2023 at 01:30 am EDT

Ascelia Pharma AB (publ) reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was SEK 37.22 million compared to SEK 29.08 million a year ago. Basic loss per share from continuing operations was SEK 1.07 compared to SEK 0.84 a year ago.

Latest news about Ascelia Pharma AB

Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024	Apr. 10	CI
Ascelia Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 09	CI
Transcript : Ascelia Pharma AB, Q4 2023 Earnings Call, Feb 09, 2024	Feb. 09
Ascelia Pharma AB Announces Start of Image Reading Phase and Re- Confirms Phase 3 SPARKLE Results by May 2024	Dec. 07	CI
Transcript : Ascelia Pharma AB, Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Ascelia Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
OptiCept Technologies Names New CFO	23-10-20	MT
Transcript : Ascelia Pharma AB, H1 2023 Earnings Call, Aug 23, 2023	23-08-23
Transcript : Ascelia Pharma AB, H1 2023 Earnings Call, Aug 18, 2023	23-08-18
Ascelia Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-18	CI
Transcript : Ascelia Pharma AB - Special Call	23-08-08
Ascelia Pharma AB Announces Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE	23-08-07	CI
Transcript : Ascelia Pharma AB, Q1 2023 Earnings Call, May 11, 2023	23-05-11
Transcript : Ascelia Pharma AB, Q1 2023 Earnings Call, May 11, 2023	23-05-11
Ascelia Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Transcript : Ascelia Pharma AB - Special Call	23-03-30
Ascelia Pharma AB Announces Demise of René Spogárd, Member of the Board of Directors	23-03-13	CI
Ascelia Pharma AB Announces the Decision of the US Patent and Trademark Office to Allow the Issuance of a Third Patent Covering the Composition of Oncoral	23-03-13	CI
Ascelia Pharma Achieves Last Patient Last Visit in the Orviglance Phase 3 Sparkle Study Which Now Includes 85 Completed Patients	23-03-03	CI
Ascelia Pharma AB Announces the Successful Completion of the Patient Enrollment in the Company's Pivotal Phase 3 Clinical Study Sparkle with the Lead Candidate Drug Orviglance	23-02-24	CI
Transcript : Ascelia Pharma AB, 2022 Earnings Call, Feb 10, 2023	23-02-10
Ascelia Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-10	CI
Ascelia Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-10	CI
Ascelia Pharma AB Announces 71 Patients Have Completed the SPARKLE Study	23-01-27	CI
Ascelia Pharma AB Announces 65 Patients Completes the Sparkle Study	22-12-29	CI

Chart Ascelia Pharma AB

Duration

Period

More charts

Company Profile

Ascelia Pharma AB is a Sweden-based pharmaceutical company focused on the development of novel oncology therapies. The Company identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The Company's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. It has completed phase I of clinical studies.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Annual General Meeting

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ASCELIA PHARMA AB	+231.16%	34.36M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research